Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.

BACKGROUND Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has become a mainstay treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance develops in most patients and ultimately compromises durable clinical benefit. Therefore, effective combination strategies to...

Li-Juan Wang, Xu Chen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.